TRAVERE THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.32 USD | -2.39% |
|
-8.28% | -40.82% |
Presenter SpeechCarter L. Gould (Analysts)Okay. Good morning, and welcome to day 3 of the Barc...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Companyâs Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
5.45
USD
Average target price
14.79
USD
Spread / Average Target
+171.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.82% | 415M | |
| -2.00% | 104B | |
| +1.85% | 97.42B | |
| +0.79% | 22.2B | |
| -17.70% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -15.32% | 15.06B | |
| +4.05% | 13.98B | |
| +35.08% | 11.66B |
- Stock Market
- Equities
- TVTX Stock
- News Travere Therapeutics, Inc.
- Transcript : Travere Therapeutics, Inc. Presents at Barclays Global Healthcare Conference 2022, Mar-17-2022 08
